Robert E. McCarthy, Ph.D., McCarthy Counseling Associates, PA and The Center for Psychophysiological Assessment and Treatment - Comment

Document ID: FDA-2011-N-0504-0009
Document Type: Public Submission
Agency: Food And Drug Administration
Received Date: August 22 2011, at 12:00 AM Eastern Daylight Time
Date Posted: August 24 2011, at 12:00 AM Eastern Standard Time
Comment Start Date: August 8 2011, at 12:00 AM Eastern Standard Time
Comment Due Date: November 7 2011, at 11:59 PM Eastern Standard Time
Tracking Number: 80ee8700
View Document:  View as format xml

View Comment

August 22, 2011 Nancy K. Stade, Deputy Director for Policy Center for Devices and Radiological Health Food and Drug Administration 5630 Fisher Lane, Room 1061 Rockville, Maryland 20852 Re: The Federal Register, Vol. 76, No. 152, pgs. 48062-48070. Proposed Rule: “Effective Date of Requirement for Premarket Approval for Cranial Electrotherapy Stimulator.” [Docket No. FDA-2011-N-0504]. Dear Ms. Stade: I am submitting this response at the request of the Food and Drug Administration (FDA) in its Proposed Rule for Cranial Electrotherapy Stimulation (CES) issued in the Federal Register on August 8, 2011 (76 F.R. 152, p. 48062). As a licensed mental health practitioner who has utilized CES in my practice for more than twenty-five years, I wanted to share with the FDA my own clinical findings on the efficacy and safety of CES. I own a group behavioral medicine practice in Myrtle Beach, South Carolina consisting of five full-time licensed mental health clinicians, and three full-time administrative staff. It is presently the only program in the entire country fully accredited by the American Association of Integrative Medicine (AAIM) for providing quality integrative healthcare. For over twenty-five years, CES has been an integral part of our treatment programs for anxiety, depression, chronic pain, and insomnia. In addition, and because it tends to increase global alpha activity in the brain, CES is rapidly becoming a cornerstone of our successful recovery work with addicts. During these twenty years, not only has CES been one of the most efficacious treatment modalities used in our practice, but there have been relatively few adverse side effects. The only complaints I have personally ever heard patients verbalize involve dizziness or nauseousness. These symptoms can usually be eliminated by reducing the intensity of the CES signal. For chronic pain patients, being able to routinely treat them systematically as well as regionally on a daily basis

Attachments:

Robert E. McCarthy, Ph.D., McCarthy Counseling Associates, PA and The Center for Psychophysiological Assessment and Treatment - Comment

Title:
Robert E. McCarthy, Ph.D., McCarthy Counseling Associates, PA and The Center for Psychophysiological Assessment and Treatment - Comment

View Attachment: View as format msw12 View as format pdf

Related Comments

    View All
Total: 171
Helen M. Sherry, Ph.D. - Comment
Public Submission    Posted: 08/24/2011     ID: FDA-2011-N-0504-0005

Nov 07,2011 11:59 PM ET
Academy of Clinical Sleep Disorders Disciplines - Comment
Public Submission    Posted: 08/24/2011     ID: FDA-2011-N-0504-0006

Nov 07,2011 11:59 PM ET
Lori R. Grifo, Of Sound Mind, Inc. - Comment
Public Submission    Posted: 08/24/2011     ID: FDA-2011-N-0504-0007

Nov 07,2011 11:59 PM ET
Kathy Platoni, Psy. D. - Comment
Public Submission    Posted: 08/24/2011     ID: FDA-2011-N-0504-0008

Nov 07,2011 11:59 PM ET
Robert E. McCarthy, Ph.D., McCarthy Counseling Associates, PA and The Center for Psychophysiological Assessment and Treatment - Comment
Public Submission    Posted: 08/24/2011     ID: FDA-2011-N-0504-0009

Nov 07,2011 11:59 PM ET